We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Self-Collection of Specimens for HPV Testing Is Feasible

By Biotechdaily staff writers
Posted on 11 Sep 2007
Although cytology-screening programs for human papillomavirus (HPV) are available in developed countries, not all women make full use of them. More...
The feasibility of using self-collected specimens for testing human papillomavirus (HPV) status among hard-to-reach women was studied in British Columbia.

Outreach nurses, recruited women in women's centers, shelters, and alleys in Vancouver's (Canada) downtown Eastside section. Participants were given a diagram that illustrated how to obtain a cervicovaginal specimen. They then placed the specimen in a tube containing Digene (Gaithersburg, MD, USA) specimen transport medium. Women were asked to collect the specimen immediately at the closest washroom or private location and to return it to the nurse.

Samples were transported to the British Columbia Center for Disease Control (Vancouver, British Columbia, Canada) within 24 hours of collection. They were analyzed for the presence of high-risk HPV DNA using the Digene HPV test, according to the manufacturer's instructions. Of the 151 participants whose specimens that were analyzed, 43 were positive for high-risk HPV. The women who tested positive were significantly younger; less educated, and reported having had more sex-trade partners than women who tested negative.

About 14% (21/151) of participants had never received a Papanicolaou smear in British Columbia (BC, Canada), as compared with 8.3% (608/7336) of women in the BC general population. This difference suggests that self-collection of specimens for HPV testing is a practical method to reach women who have not previously participated in cervical cancer screening programs.

The study was initiated by Dr. Gina Ogilvie, assistant professor, University of British Columbia (Vancouver, Canada) and was published in the August 2007 issue of the Canadian Medical Association Journal (CMAJ).


Related Links:
British Columbia Center for Disease Control
Digene
University of British Columbia

Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
hCG Whole Blood Pregnancy Test
VEDALAB hCG-CHECK-1
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.